Parameter
| Biomarker | IGF-1/IGF-1R | Full name | Insulin-like Growth Factor-1 / Receptor | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis, therapeutic targets |
| Disease | PCa | Disease Subtypes | / | ||
| Organ | Prostate | Test Sample / Technology Platform | Serum (ELISA, CLIA, IHC) | ||
| Pathobiological Mechanisms | After binding to its receptor IGF-1R, IGF-1 activates signaling pathways such as PI3K/Akt/mTOR and Ras/Raf/MAPK, promoting cell survival, proliferation, migration, and therapeutic resistance. | ||||
| Clinical Availability Status | Research validation/clinical trial | ||||
| Notes and Dynamics | Targeted IGF-1R drugs have shown limited efficacy in Phase II clinical trials, likely due to the absence of predictive biomarkers. | ||||